



	2019	2022	2023	2024	Δ 2024-2019	GRI Indicator
Climate Change – Public Targets ¹						
Scope 1 + 2 (metric ton (mt) CO ₂ e) ^{2,3,4}	1,266,345	1,127,846	1,108,036	1,078,346	↓ 15%	305-3
Renewable Energy (%) ²	9.5%	6.9%	9.9%	14.4%	↑ 51%	-
Scope 3 – Business travel (mt CO ₂ e) ^{5,11}	421,399	101,725	186,396	188,309	↓ 55%	305-3
Scope 3 – Upstream transportation & distribution (mt CO ₂ e) ^{5,9}	200,873	389,988	257,319	154,001	↓ 23%	305-3
Scope 3 – Suppliers of purchased goods and services by spend with science-based targets (%) ⁶		29%	51%	65%	--	305-3

Pfizer is committed to achieving the voluntary Net-Zero standard by 2040. Our near-term climate goals, approved by the Science Based Targets initiative, are to:

- Reduce Scope 1+2 greenhouse gas (GHG) emissions **46%** by 2030 from a 2019 baseline.
- Source **80%** of electricity from renewables by 2025 and **100%** by 2030.
- Reduce GHG emissions from business travel **25%** by 2025 from a 2019 baseline.
- Reduce GHG emissions from upstream transportation and distribution **10%** by 2025 from a 2019 baseline.
- Catalyze **64%** of our suppliers of goods and services by spend to set science-based targets by 2025.

	2019	2022	2023	2024	Δ 2024-2019	Δ 2024-2023	GRI Indicator
Climate Change – Additional Metrics ¹							
Scope 1 (mt CO ₂ e) ^{2,3}	695,112	644,565	617,404	613,218	↓ 12%	↓ 1%	305-1
Scope 2, market-based (mt CO ₂ e) ^{2,4}	571,233	483,281	490,632	465,128	↓ 19%	↓ 5%	305-2
Scope 2, location-based (mt CO ₂ e) ^{2,4}	558,958	498,822	461,084	450,093	↓ 20%	↓ 2%	305-2
Scope 1 + 2 Emissions Intensity (mt CO ₂ e/million USD revenue) ^{2,3,4}	31.0	11.2	18.9	16.9	↓ 45%	↓ 11%	305-4
Energy Consumed (MWh) ²	4,787,389	4,558,232	4,466,375	4,437,907	↓ 7%	↓ 1%	302-1
Energy Intensity (MWh/million USD revenue) ²	117.0	45.1	75.0	69.8	↓ 40%	↓ 7%	302-3
Scope 3 – Purchased goods and services (mt CO ₂ e) ^{5,7}	1,900,504	8,247,666	3,401,334	2,786,489	↑ 47%	↓ 18%	305-3
Scope 3 – Capital goods (mt CO ₂ e) ^{5,7}	101,679	282,414	126,588	119,357	↑ 17%	↓ 6%	305-3
Scope 3 – Fuel-and-energy-related activities not in Scope 1 or 2 (mt CO ₂ e) ^{5,8}	252,909	262,990	263,780	254,803	↑ 0.7%	↓ 3%	305-3
Scope 3 – Waste generated in operations (mt CO ₂ e) ^{5,10}	9,512	8,650	8,795	5,435	↓ 43%	↓ 38%	305-3
Scope 3 – Employee commuting (mt CO ₂ e) ^{5,12}	60,645	38,557	21,745	20,564	↓ 66%	↓ 5%	305-3
Scope 3 – Upstream leased assets (mt CO ₂ e) ^{5,13}	36,273	30,449	26,497	15,511	↓ 57%	↓ 41%	305-3
Scope 3 – Downstream transportation and distribution (mt CO ₂ e) ¹⁴	99,576	8,351	4,446	3,397	↓ 97%	↓ 24%	305-3
Scope 3 – Investments (mt CO ₂ e) ^{5,15}	33,892	6,939	6,754	7,342	↓ 78%	↑ 9%	305-3
Scope 3 – Total (mt CO ₂ e)	3,117,262	9,377,729	4,303,654	3,555,207	↑ 14%	↓ 17%	305-3



	2022	2023	2024	Δ 2024-2023	GRI Indicator
Water ^{1,16,17}					
Water withdrawal excluding non-contact cooling water (million m ³)	12.3	12.3	12.1	↓ 2%	303-3
Water withdrawal including non-contact cooling water (million m ³)	28.7	31.9	30.9	↓ 3%	303-3
Third-party water (million m ³)	8.0	7.7	7.5	↓ 2%	303-3
Surface water withdrawal (million m ³)	0.9	0.8	0.7	↓ 6%	303-3
Groundwater withdrawal (million m ³)	19.9	23.4	22.7	↓ 3%	303-3
Brackish/seawater withdrawal (million m ³)	0	0	0	-	303-3
Water discharged (million m ³)	25.8	29.0	27.7	↓ 5%	303-4
Water consumed (million m ³)	2.9	2.9	3.3	↑ 14%	303-5
Waste ^{1,18, 19}					
Hazardous waste generated (thousand metric tons)	76.5	80.4	79.9	↓ 1%	306-3
Hazardous waste diverted from disposal (thousand metric tons)	7.5	10.4	12.6	↑ 21%	306-4
Hazardous waste incinerated with energy recovery (thousand metric tons)	47.6	51.3	51.9	↑ 1%	306-5
Hazardous waste incinerated without energy recovery (thousand metric tons)	17.0	13.8	10.1	↓ 27%	306-5
Hazardous waste landfilled (thousand metric tons)	0.03	0.03	0.04	↑ 48%	306-5
Hazardous waste other treatment (thousand metric tons)	4.5	4.8	5.2	↑ 9%	306-5
Hazardous waste disposed (thousand metric tons)	69.1	70.0	67.3	↓ 4%	306-5
Hazardous waste diverted from disposal (%)	10%	13%	16%	-	306-4
Non-hazardous waste generated (thousand metric tons)	34.7	36.2	35.1	↓ 3%	306-3
Non-hazardous waste diverted from disposal (thousand metric tons)	18.4	19.2	19.7	↑ 2%	306-4
Non-hazardous waste incinerated with energy recovery (thousand metric tons)	5.0	5.5	7.8	↑ 40%	306-5
Non-hazardous waste incinerated without energy recovery (thousand metric tons)	0.6	1.2	0.7	↓ 38%	306-5
Non-hazardous waste landfilled (thousand metric tons)	10.4	10.1	6.7	↓ 34%	306-5
Non-hazardous waste other treatment (thousand metric tons)	0.3	0.2	0.2	↑ 1%	306-5
Non-Hazardous waste disposed (thousand metric tons)	16.3	17.0	15.4	↓ 9%	306-5
Non-hazardous waste diverted from disposal (%)	53%	53%	56%	-	306-4



	2022	2023	2024	Δ 2024-2023	GRI Indicator
Air Emissions ¹					
Volatile organics (thousand kg)	440.4	512.4	283.6	↓ 45%	305-7
Health & Safety					
Fatalities ²¹	0	0	2	-	403-9 403-10
Recordable injuries & illnesses	251	258	256	↓ 1%	403-9 403-10
Lost time injuries & illnesses	107	114	123	↑ 8%	403-9 403-10
Hours worked (millions)	169.6	172.9	165.1	↓ 5%	403-9 403-10
Total Injury & Illness Rate (Recordable cases per 200,000 hours worked) ²⁰	0.30	0.30	0.31	↑ 4%	403-9 403-10
Total Lost Time Injury & Illness Rate (Lost time cases per 200,000 hours worked) ²⁰	0.13	0.13	0.15	↑ 13%	403-9 403-10
Fleet Safety (Collisions per million km driven)	7.98	7.93	7.54	↓ 5%	-
Compliance					
Number of EHS penalties paid ²²	7	1	4	-	307-1
EHS Penalties paid (currency equivalent USD) ²²	15,500	111,600	18,600	-	307-1
Supplier EHS assessments (number performed)	116	109	90	-	308-2

NOTES

↓=decrease (reduction) ↑=increase

Notes

¹ Pfizer’s organizational boundaries for environmental performance include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted, reported absolute, using reporting boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol.



NOTES


Climate Change

Scope 1 & 2

- ² Data presented represents information available as of May 31, 2025, including certain estimates and assumptions. Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology. Baseline year data (2019) has been independently verified to the limited assurance level; 2021-2024 data is independently verified to the reasonable assurance level. See Pfizer’s [website](#) for our GHG calculation methodology and assurance reports.
- ³ Scope 1 emissions include CO₂, CH₄, N₂O, SF₆, and refrigerants using IPCC Fifth Assessment Report (AR5-100 year) Global Warming Potential (GWP) rates; volatile organic emissions are calculated using an emission factor representative of solvents typically used by Pfizer sites.
- ⁴ Scope 2 emissions are reported in accordance with GHG Protocol Scope 2 Guidance as location- and market-based emissions. Location-based emissions are calculated based on the average emissions intensity of the grid for the region where energy is consumed. Market-based emissions are calculated based on the electricity procured by individual locations, with emission factors derived from contractual instruments.

Scope 3

- ⁵ Data presented represents information available as of May 31, 2025, including certain estimates and assumptions. Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology. 2019 and 2024 data is independently verified to the limited assurance level. Seagen's Scope 3 emissions for 2024 are included in Pfizer's 2024 data, however, Seagen's 2019 Scope 3 emissions were determined to be non-material (i.e., less than 5% of the total emissions per category) and were therefore not added to our baseline. See Pfizer’s [website](#) for our GHG calculation methodology and assurance reports.
- ⁶ Supplier engagement – Tracking of the Scope 3 supplier engagement goal was initiated in 2021. We include companies publicly committed to setting science-based targets through the Science Based Target Initiative (SBTi), companies with SBTi-validated targets, and companies with Scope 1 and 2 targets set at a level equivalent to SBTi criteria.
- ⁷ Purchased goods and services & capital goods – 2019, 2023 and 2024 emissions calculated based on spend using US EPA Supply Chain Greenhouse Gas Emission Factors (v1.2 by NAICS-6), adjusted for inflation. 2022 emissions calculated using emission factors determined using average data methodology and DEFRA 2011 Table 13 emission factors adjusted for inflation.
- ⁸ Fuel-and-energy-related activities – 2024 fuel-related emissions calculated using 2024 UK Government GHG Conversion Factors for Company Reporting. Emissions associated with production and transmission and distributions of electricity, heat and steam calculated using both 2021 and 2024 UK Government GHG Conversion Factors and 2024 IEA Emission Factors. For non-UK sites, transmission & distribution emissions include CO₂ only.
- ⁹ Upstream transportation & distribution (Category 4) – Emissions are calculated from Pfizer and third-party datasets. As the result of improvements in our methodology accounting for logistics and tertiary packaging material weights, we have recalculated historical Category 4 emissions, including the 2019 baseline. In 2024 we continued applying low emissions fuels certificates provided by logistics suppliers. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers are excluded as they are included in Category 1, Purchased Goods and Services. Due to limited data availability, emissions associated with market logistics and the operation of third-party logistics centers outside of the US are not included in reporting. We continue to look for opportunities to move product shipments from air to ocean and are working with our logistics providers to transition to low emission fuels and vehicles where possible.
- ¹⁰ Waste generated in operations – 2024 emissions calculated using UK Government GHG Conversion Factors for Company Reporting (2024). DEFRA's 2024 combustion emission factor decreased by 70% from 2023 contributing to a decrease in annual category 5 emissions.
- ¹¹ Business travel – Emissions calculated by Pfizer’s travel partner, using a proprietary methodology certified under ISO 14064-1:2018 & 2019, and by Pfizer’s US fleet reimbursement management provider. Air travel emissions for all years, including the 2019 baseline, have been adjusted to include well-to-wheel (WTW) emissions in accordance with the GHG Protocol. We have added estimates to the 2019- 2024 results to account for travel booked outside Pfizer’s travel system, which account for approximately 10% of total business travel emissions.



NOTES

Scope 3

- ¹² Employee commuting – Emissions estimated using 2025 US EPA Climate Leaders GHG and 2024 DEFRA emission factors. 2019 to 2022 include estimated emissions for colleagues working remotely.
- ¹³ Upstream leased assets – Emissions for 2023 and 2024 were calculated from actual energy consumption where available following the same methodology used for calculating Scope 1 & 2 emissions (see notes 3 & 4 above). Emissions from other leased locations were calculated based on floor space using average emission factors. In 2024 we updated our estimation methodology to reflect location type (e.g., laboratory, office, storage), resulting in a reduction in emissions.
- ¹⁴ Downstream transportation and distribution – Emissions provided for parts of US and Europe only. 2023 emissions reduction due to switch to emission factors from the Global Logistics Emissions Council (GLEC) framework. We initiated a project in 2024 to improve our calculation methodology for this category and have implemented the change for the 2025 reporting year.
- ¹⁵ Investments – Emissions data provided by Pfizer’s joint venture operations where we have influence and/or operational control.

Water

- ¹⁶ Pfizer strives to reduce freshwater use from its internal operations. Our [Water Stewardship position statement](#) describes our efforts to be good stewards of water with a particular focus on water stressed areas. In 2024, the manufacturing schedule included more water-intensive processes compared to prior years. As production focus shifts, we continuously explore strategies for water stewardship and resource efficiency.
- ¹⁷ 2023 & 2024 data is independently verified to the limited assurance level. See Pfizer’s [website](#) for our calculation methodology and assurance reports.

Waste

- ¹⁸ Pfizer strives to reduce waste from its operation through applying a hierarchy of control of handling waste: avoid, reduce, reuse, recycle, disposal. Each site has established targets to improve the circularity of their waste, and we benchmark our performance against others in our industry. Pfizer continues to enhance waste management practices through our hierarchy of control of handling waste.
- ¹⁹ 2023 & 2024 hazardous waste data is independently verified to the limited assurance level. See Pfizer’s [website](#) for our calculation methodology and assurance reports.

Health & Safety

- ²⁰ Pfizer’s global total injury & illness rate and total lost time injury rate is based on OSHA recording criteria.
- ²¹ Work-related injuries or illnesses that led to loss of life. Both reported cases in 2024 were related to motor vehicle collisions.

Compliance

- ²² Compliance with applicable environmental, health and safety (EHS) laws in the jurisdictions where we operate, complemented by our internal EHS Standards, is a foundation of our EHS program. Pfizer is dedicated to maintaining full EHS compliance, and when potential non-compliance is identified, including when identified through self-assessment and compliance assurance programs, prompt corrective action is required. Our internal EHS Standards and routine internal EHS audits assist in maintaining compliance and providing a strong driver for continuous improvement. All alleged non-compliance events listed in the table have been resolved.